Patient disposition. Boxes highlighted in pink indicate best response to combination therapy among subpopulations of patients who did and did not proceed to ASCT. Efficacy-evaluable patients who discontinued treatment owing to AEs during combination therapy are indicated by dashed lines; patients who completed combination therapy but did not enroll in the brentuximab monotherapy phase are shown separately.